Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline's Advair, in combination with Pfizer Inc's Spiriva, has failed to reduce exacerbations in patients with the respiratory illness chronic obstructive pulmonary disease in a recent study.
Subscribe to our email newsletter
A Canadian study to determine which inhaler regimen would best prevent a bout of worsening symptoms in chronic obstructive pulmonary disease (COPD) found that there was not much difference between the patient groups.
Although the combination of Advair and Spiriva improved quality of life and lung function, it did not affect the number of exacerbations in patients with moderate or severe COPD.
The proportion of patients who had exacerbations was 63% in the group given Spiriva plus placebo, 65% in the group given Spiriva plus Serevent, another Glaxo drug, and 60% in the group given Spiriva plus Advair. The trial involved 449 adults with COPD.